GlaxoSmithKline spinout SR One strikes $500m hard cap for debut independent fundraise
Transatlantic biotech investor SR One has raised its first fund in the wake of spinning out from pharmaceutical giant GlaxoSmithKline.
Transatlantic biotech investor SR One has raised its first fund in the wake of spinning out from pharmaceutical giant GlaxoSmithKline.
Recent Comments